A major US cohort study found that more than one in four women living with HIV used cannabis over an 18-month period, with smoking as the dominant method and daily use reported by 15% of participants. These findings reveal that cannabis use in this population is common, dynamic, and often accompanied by other substance use, underscoring the need for routine clinical screening.

Women living with HIV in the United States are aging into a landscape of expanding cannabis legalization, yet clinicians have had remarkably little rigorous data on how frequently these women use cannabis, what products they choose, or how their use changes over time. This population faces unique medical complexity, including polypharmacy, chronic inflammation, and elevated rates of co-occurring substance use, making it especially important to understand real-world cannabis consumption. Without descriptive data of this kind, providers cannot design informed screening protocols or anticipate drug interaction risks in a group already managing complicated antiretroviral regimens.

This study drew on data from the Women’s Interagency HIV Study (WIHS), one of the largest and longest-running federally funded prospective cohort studies of women with HIV in the United States. The investigators analyzed self-reported cannabis use across three semiannual visits from April 2018 through September 2019, capturing a period during which cannabis legalization continued to expand across multiple US jurisdictions. The cohort of 1,246 women was predominantly Black or African American (65%), had a median age of 52, and half reported annual household incomes below $12,000. The study aimed not to test hypotheses about cannabis efficacy or harm, but rather to establish a detailed descriptive portrait of who is using cannabis, how often, and by what method.

The period prevalence of any cannabis use was 27%, roughly double national estimates for adult women. Daily or more frequent use was reported by 15% of the cohort. Among those who used cannabis, 96% smoked it, 30% consumed edibles, and 18% vaped, with many women using multiple modes. Notably, half of all participants shifted between frequency categories across the three visits, revealing highly dynamic rather than stable use patterns. Higher-potency product consumption through vaping or edibles was significantly more common in states with legal cannabis sales. Cannabis use co-occurred substantially with alcohol (69% vs. 37%), cigarettes (61% vs. 29%), and other drugs (16% vs. 4%) compared to non-users. All use data were self-reported without biomarker confirmation, and the restriction to women completing all three visits may underrepresent the most marginalized participants. The authors emphasize that these descriptive findings are a necessary foundation for subsequent etiologic and outcome-focused research.

This study does exactly what good descriptive epidemiology should do: it tells us what is actually happening with cannabis in a population we care about, without pretending to know why. The finding that 27% of women with HIV used cannabis and that half of users shifted their frequency category over just 18 months is striking because it challenges the assumption that cannabis consumption is a fixed behavior amenable to a single-point screening question. The 96% smoking prevalence in this group also matters clinically because inhaled cannabis carries pulmonary risks that are especially relevant in women already navigating chronic inflammation and immune compromise.

In practice, I ask patients living with HIV about cannabis use at every visit, not just once. I inquire specifically about method of consumption, not just frequency. For patients who smoke cannabis daily and are on complex antiretroviral regimens, I have conversations about the respiratory tradeoffs and about whether edibles or other non-combustion routes might serve them better. This study reinforces that approach. The polydrug use finding also reminds me to keep the screening lens wide. Cannabis is rarely the only substance in the picture for this population.

This study sits at the foundation of the research arc rather than near its clinical application endpoint. It provides the prevalence, mode, and frequency data that are prerequisites for any future work linking cannabis use patterns to antiretroviral adherence, immune function, neurocognitive outcomes, or quality of life in women with HIV. Until now, clinicians working with this population have had to extrapolate from general population surveys or from studies of men who have sex with men, neither of which captures the demographic or medical reality of older, lower-income women managing chronic HIV. The dynamic use patterns documented here further argue against cross-sectional approaches in future studies; longitudinal measurement will be essential to avoid misclassifying exposure.

For clinicians, the pharmacological consideration is straightforward but important: cannabis constituents, particularly THC and CBD, interact with cytochrome P450 enzymes (CYP3A4 and CYP2C19) that also metabolize several antiretroviral agents, including protease inhibitors and some integrase inhibitors. The high rate of daily smoking in this cohort means sustained enzyme exposure, not occasional perturbation. Vaping and edibles introduce different absorption pharmacokinetics that further complicate predictions about drug levels. The most actionable recommendation from this evidence is to incorporate mode-specific, repeated cannabis use screening into routine HIV care visits, rather than relying on a single baseline question about whether a patient “uses marijuana.”

Physician-Led, Whole-Person Care

A doctor who takes the time to truly understand you.

Personal care that starts with listening and is guided by experience and ingenuity.

Health, Longevity, Wellness

One-on-One Cannabis Guidance

Metabolic Balance

Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care